ClinicalTrials.gg
RecruitingNCT06607029Updated Mar 11, 2025

Opioid-free Anesthesia Protocol for Neurosurgical Supratentorial Tumor Resection

An interventional study of the opioid-based control group and the opioid-free anesthesia group in Supratentorial Tumors, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Opioids have many side effects, such as constipation, urinary retention, itchy skin, respiratory depression, and postoperative nausea and vomiting. These side effects can lead to delayed recovery, longer hospital stays, and increased health care costs. Opioid-free anesthesia is the combination of anti-nociceptive drugs to block the different pathways involved in the transmission of nociceptive information, control pain, avoid opioid-related adverse reactions, and promote patient recovery. At present, opioid-free anesthesia is not widely used in craniocerebral surgery in neurosurgery, and the relevant clinical data are extensive. Therefore, the investigators urgently need to conduct a randomized controlled study to provide clinical evidence for the efficacy and safety of opioid-free anesthesia in neurosurgical patients.

Read the detailed description

Data sharing plan: The deidentified participant data reported in this study could be made available to researchers upon approval by the corresponding author (Dr. Ruquan Han, ruquan.han@ccmu.edu.cn) immediately after publication. The reasonable request should provide a formal protocol for database use that has been approved by the ethics institutions.

02

Conditions studied

  • Supratentorial Tumors
03

In context

Supratentorial Neoplasms

22 studies on the registry are indexed under Supratentorial Neoplasms; 3 are open to participants now.

This study's planned enrollment of 170 is above the median of 80 across 20 interventional studies indexed under Supratentorial Neoplasms.

Browse Supratentorial Neoplasms studies →

Lead sponsor

Beijing Tiantan Hospital is the lead sponsor of 489 studies on the registry; 293 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled to undergo craniotomy for supratentorial tumors with general anesthesia;
  • 18 years≤age≤65 years;
  • (ASA) physical status of I to III;
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Patients with a (BMI)≥35 kg/m2;
  • Patients with severe hepatic and renal insufficiency;
  • Patients with cognitive dysfunction, aphasia and other states that do not cooperate with the assessment;
  • Preoperative magnetic resonance imaging of the head showed midline displacement >5 mm;
  • Patients undergoing electrophysiological monitoring during surgery;
  • Pregnant or lactating patients.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
170 participants (estimated)

Study arms

  • Active comparator
    the opioid-based control group

    Drug: the opioid-based control group

  • Experimental
    the opioid-free anaesthesia group

    Drug: the opioid-free anesthesia group

Interventions

  • Drugthe opioid-based control group

    Intraoperative analgesia will be administered with conventional opioid drugs such as sufentanil and remifentanil.

  • Drugthe opioid-free anesthesia group

    The patients will be administered with an opioid-free strategy during surgery. The investigator will use esketamine, dexmetopidine, and local anesthesia to control perioperative pain.

06

What researchers measure

Primary outcomes

  1. the quality of recovery-15(QoR-15) score on the second day after surgery

    Quality of Recovery-15(QoR-15) score, as a tool to evaluate recovery quality during perioperative period. The QoR-15 scale was used to assess patients' postoperative recovery. Each item is scored on a 10-point scale, from 0 (worst recovery) to 150 (best recovery).

    Time frame: on the second day after surgery

Secondary outcomes

  1. The QoR-15 score on the 5th day after surgery

    Time frame: on the 5th day after surgery

  2. The incidence of nausea and vomiting within 48 hours after surgery

    Time frame: 48 hours after surgery

  3. The NRS pain score on the second and 5th days after surgery

    Time frame: on the second and 5th days after surgery

  4. The sleep quality on the second and 5th days after surgery

    Time frame: on the second and 5th days after surgery

  5. The incidence of chronic pain at 3 and 6 months after surgery

    Time frame: at 3 and 6 months after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data sharing plan: The deidentified participant data reported in this study could be made available to researchers upon approval by the corresponding author (Dr. Ruquan Han, ruquan.han@ccmu.edu.cn) immediately after publication. The reasonable request should provide a formal protocol for database use that has been approved by the ethics institutions.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Dec 2025, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2024
First posted
Sep 23, 2024
StartActual
Oct 21, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Mar 31, 2026
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06607029
Responsible party
Ruquan Han (Head of Anesthesiology, Beijing Tiantan Hospital) — Principal investigator
First posted
Sep 23, 2024
Start date
Oct 21, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Mar 11, 2025

Study contacts

Han
Contact
ruquan.han@ccmu.edu.cn
010-59976660

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion